AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33127746 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC5AC-depleted pancreatic cancer cells
Number of subjects: 2
Study 32493514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8mg/kg body weight i.v. once, 12 mg/kg for patients <30kg BW, max 800 mg)
Number of subjects: 200
Study 32493514 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl) i.v. once
Number of subjects: 200
Study 35194818 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week lifestyle medicine program consisting of five lifestyle factors
Number of subjects: 18
Study 35194818 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 18
Study 32142556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic sensory stimulation (RSS) treatment with different parameters
Number of subjects: 0
Study 32142556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic sensory stimulation (RSS) treatment with different specifications
Number of subjects: 0
Study 35331538 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg/day for 24 weeks)
Number of subjects: 32
Study 35331538 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 32
Study 34441755 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 0
Study 34441755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 0
Study 34441755 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir (EVG/c)
Number of subjects: 0
Study 34441755 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC)
Number of subjects: 0
Study 34441755 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from boosted PI or efavirenz to RAL, DTG, or BIC
Number of subjects: 0
Study 34441755 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to Elvitegravir (EVG/c)
Number of subjects: 0
Study 34441755 — intervention group
Group type: COMPARATOR
Intervention: Switching trials between INSTIs
Number of subjects: 0
Study 32121218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DYM (100 mg)
Number of subjects: 125
Study 32121218 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DYM (150 mg)
Number of subjects: 125
Study 32121218 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose DYM with TCR (100 mg + 50 mg)
Number of subjects: 125
Study 32121218 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DYM with TCR (150 mg + 25 mg)
Number of subjects: 125
Study 32121218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 35848979 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapies combined with swallowing training
Number of subjects: 71
Study 35848979 — intervention group
Group type: COMPARATOR
Intervention: Swallowing training and rehabilitation consultation (Control)
Number of subjects: 71
Study 33580200 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mutations of BRAF, FBXW7, NRAS, and XPO1 genes
Number of subjects: 600
Study 33580200 — intervention group
Group type: COMPARATOR
Intervention: Patients without mutations of BRAF, FBXW7, NRAS, and XPO1 genes
Number of subjects: 600
Study 33580200 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving ≥2 lines of treatment
Number of subjects: 600
Study 33580200 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients dying in winter months
Number of subjects: 600
Study 33580200 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 11q deletion
Number of subjects: 600
Study 33580200 — intervention group
Group type: COMPARATOR
Intervention: Patients without 11q deletion
Number of subjects: 600
Study 32702360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof IOL
Number of subjects: 381
Study 32702360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis IOL
Number of subjects: 381
Study 32702360 — intervention group
Group type: EXPERIMENTAL
Intervention: Envista IOL
Number of subjects: 381
Study 34134818 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Number of subjects: 179
Study 34134818 — intervention group
Group type: COMPARATOR
Intervention: Single-diagnosis CBT protocol
Number of subjects: 179
Study 34134818 — intervention group
Group type: EXPERIMENTAL
Intervention: Homework quality
Number of subjects: 179
Study 34134818 — intervention group
Group type: EXPERIMENTAL
Intervention: Homework compliance
Number of subjects: 179
Study 34134818 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater homework quality and compliance
Number of subjects: 179
Study 32398441 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% lidocaine with 1.0 ppm DEX
Number of subjects: 19
Study 32398441 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% lidocaine with 2.0 ppm DEX
Number of subjects: 19
Study 32398441 — intervention group
Group type: COMPARATOR
Intervention: 1.8% lidocaine with 1:80,000 adrenaline
Number of subjects: 19
Study 33846100 — intervention group
Group type: EXPERIMENTAL
Intervention: 340B hospitals
Number of subjects: 500
Study 33846100 — intervention group
Group type: COMPARATOR
Intervention: non-340B hospitals
Number of subjects: 500
Study 33273369 — intervention group
Group type: EXPERIMENTAL
Intervention: MUSKARDIA
Number of subjects: 2674
Study 33273369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2674
Study 36484187 — intervention group
Group type: EXPERIMENTAL
Intervention: Governor vessel moxibustion combined with warming acupuncture
Number of subjects: 64
Study 36484187 — intervention group
Group type: COMPARATOR
Intervention: Warming acupuncture
Number of subjects: 64
Study 36484187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 34628925 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard haematological care associated with palliative care (PC)
Number of subjects: 0
Study 34628925 — intervention group
Group type: COMPARATOR
Intervention: Standard haematological care only
Number of subjects: 0
Study 36288808 — intervention group
Group type: COMPARATOR
Intervention: Preconception intervention groups (A+B)
Number of subjects: 13500
Study 36288808 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy intervention groups
Number of subjects: 13500
Study 36288808 — intervention group
Group type: COMPARATOR
Intervention: Preconception and pregnancy interventions
Number of subjects: 13500
Study 36288808 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy and early childhood intervention groups
Number of subjects: 13500
Study 36288808 — intervention group
Group type: COMPARATOR
Intervention: Preconception, pregnancy, and early childhood interventions
Number of subjects: 13500
Study 36288808 — intervention group
Group type: COMPARATOR
Intervention: Preconception intervention groups
Number of subjects: 13500
Study 34116700 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rVA576 eye drops, administered twice a day for 8 weeks
Number of subjects: 3
Study 34116700 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rVA576 eye drops
Number of subjects: 3
Study 33075444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - received a brochure with supplementary advice, tips, and monthly counselling on food texture introduction.
Number of subjects: 60
Study 33075444 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - received current French recommendations.
Number of subjects: 60
Study 32369631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone Therapy
Number of subjects: 0
Study 33544937 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy A - Education delivered directly to families
Number of subjects: 1426
Study 33544937 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy B - Education delivered first to teachers, then to families
Number of subjects: 1426
Study 33544937 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy C - Education delivered only to healthcare coordinators, then to teachers and families
Number of subjects: 1426
Study 33544937 — intervention group
Group type: COMPARATOR
Intervention: Control group - No intervention
Number of subjects: 1426
Study 32886447 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (PGB) monotherapy (150 mg twice daily)
Number of subjects: 58
Study 32886447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Pregabalin (PGB) (150 mg twice daily) and Milnacipran (MLN) (50 mg twice daily)
Number of subjects: 58
Study 32195927 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily educational text messages on diabetes and reminders for 6 months
Number of subjects: 216
Study 32195927 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 216
Study 34559571 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom management journal at the start of SACT
Number of subjects: 64
Study 34559571 — intervention group
Group type: COMPARATOR
Intervention: Symptom management journal after completing two cycles of SACT
Number of subjects: 64
Study 32182123 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (600 mg)
Number of subjects: 10
Study 36181564 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 118
Study 36181564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SDD)
Number of subjects: 118
Study 33482910 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP-I-ALC (povidone-iodine-alcohol)
Number of subjects: 16
Study 33482910 — intervention group
Group type: COMPARATOR
Intervention: CHG-ALC (chlorhexidine-alcohol)
Number of subjects: 16
Study 32838676 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Health Action Management (WHAM)
Number of subjects: 139
Study 32838676 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 139
Study 35197356 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile sedatives
Number of subjects: 96
Study 35197356 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedatives
Number of subjects: 96
Study 33971386 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 1631
Study 33971386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1631
Study 616173446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 177
Study 616173446 — intervention group
Group type: COMPARATOR
Intervention: Regular recommended HF therapy (including maximized beta-blockade)
Number of subjects: 177
Study 35022014 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (10 mg twice daily)
Number of subjects: 70
Study 35022014 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (100 mg daily initially followed by 200 mg daily after week 4)
Number of subjects: 70
Study 33815503 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session treatment group with BioRoot RCS
Number of subjects: 12
Study 33815503 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session treatment group with BioRoot RCS
Number of subjects: 12
Study 32466128 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic and psychosocial factors supporting sustainable agriculture practices (SAPs)
Number of subjects: 300
Study 32466128 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of planned behavior (TPB) dimensions
Number of subjects: 300
Study 32466128 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy measures supporting socioeconomic and psychosocial factors
Number of subjects: 300
Study 34487844 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil (8 g daily for 12 weeks)
Number of subjects: 67
Study 34487844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 34959944 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic powder containing Lactobacillus acidophilus, Bifidobacterium lactis, and S. salivarius K12
Number of subjects: 25
Study 34959944 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control powder
Number of subjects: 25
Study 34282608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight-fitting method with a clip
Number of subjects: 30
Study 34282608 — intervention group
Group type: COMPARATOR
Intervention: General-fitting method
Number of subjects: 30
Study 32353535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Definition Chromoendoscopy (HD-CE) with indigo carmine, collection of 32 random biopsies, and targeted biopsies or polypectomies
Number of subjects: 305
Study 32353535 — intervention group
Group type: COMPARATOR
Intervention: High-Definition White Light Endoscopy (HD-WLE), collection of 32 random biopsies, and targeted biopsies or polypectomies
Number of subjects: 305
Study 32353535 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Definition Chromoendoscopy (HD-CE)
Number of subjects: 305
Study 32353535 — intervention group
Group type: COMPARATOR
Intervention: High-Definition White Light Endoscopy (HD-WLE)
Number of subjects: 305
Study 35108029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Vacuum-Assisted Biopsy (VAB)
Number of subjects: 318
Study 35108029 — intervention group
Group type: COMPARATOR
Intervention: Imaging after NST
Number of subjects: 318
Study 35108029 — intervention group
Group type: COMPARATOR
Intervention: VAB alone
Number of subjects: 318
Study 35108029 — intervention group
Group type: COMPARATOR
Intervention: Combinations of imaging and VAB
Number of subjects: 318
Study 34747917 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem (diltiazem group)
Number of subjects: 70
Study 34747917 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (placebo group)
Number of subjects: 70
Study 34747917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 35852267 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergonovine plus oxytocin
Number of subjects: 160
Study 35852267 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 160
Study 33793289 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout intervention
Number of subjects: 40
Study 33793289 — intervention group
Group type: EXPERIMENTAL
Intervention: Work culture prioritizing person-centered care
Number of subjects: 40
Study 33793289 — intervention group
Group type: EXPERIMENTAL
Intervention: Robust management skills and practices
Number of subjects: 40
Study 33793289 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunities for professional development and self-care
Number of subjects: 40
Study 32197107 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose primary series (days 1 and 91)
Number of subjects: 1800
Study 32197107 — intervention group
Group type: EXPERIMENTAL
Intervention: One primary dose (day 1)
Number of subjects: 1800
Study 32197107 — intervention group
Group type: EXPERIMENTAL
Intervention: One primary dose plus booster (days 1 and 365)
Number of subjects: 1800
Study 32197107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1800
Study 35545057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin treatment for 6 weeks
Number of subjects: 41
Study 35545057 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 41
Study 32706261 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ (80 mg)
Number of subjects: 11
Study 32706261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 35001842 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise only
Number of subjects: 72
Study 35001842 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure only
Number of subjects: 72
Study 35001842 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure plus exercise
Number of subjects: 72
Study 35001842 — intervention group
Group type: COMPARATOR
Intervention: No exercise/no exposure therapy (control)
Number of subjects: 72
Study 34020452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 2691
Study 34020452 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn soy whey blend with fortified vegetable oil (CSWB w/oil)
Number of subjects: 2691
Study 34020452 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Cereal Plus with amylase (SC + A)
Number of subjects: 2691
Study 34020452 — intervention group
Group type: COMPARATOR
Intervention: Corn Soy Blend Plus with fortified vegetable oil (CSB+ w/oil)
Number of subjects: 2691
Study 34218509 — intervention group
Group type: EXPERIMENTAL
Intervention: High n-3 plus low n-6 dietary intervention (H3-L6)
Number of subjects: 82
Study 34218509 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 82
Study 34976106 — intervention group
Group type: EXPERIMENTAL
Intervention: Path-type health education
Number of subjects: 162
Study 34976106 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 162
Study 33167882 — intervention group
Group type: EXPERIMENTAL
Intervention: $25 gift card at each follow-up visit
Number of subjects: 0
Study 33167882 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 0
Study 36154311 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning short-term intervention delivered via app
Number of subjects: 0
Study 36154311 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning short-term intervention delivered via email
Number of subjects: 0
Study 36154311 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34420765 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate infant feeding support
Number of subjects: 997
Study 34420765 — intervention group
Group type: COMPARATOR
Intervention: Inadequate infant feeding support
Number of subjects: 997
Study 32207413 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric muscle energy technique with cervical segmental mobilisation
Number of subjects: 40
Study 32207413 — intervention group
Group type: COMPARATOR
Intervention: Static stretching exercises with cervical segmental mobilisation
Number of subjects: 40
Study 34279976 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-Centered Care Planning (PCCP)
Number of subjects: 22
Study 34279976 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 22
Study 34279976 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management
Number of subjects: 22
Study 34616808 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (2 g) added to a low FODMAP diet
Number of subjects: 100
Study 34616808 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to a low FODMAP diet
Number of subjects: 100
Study 34616808 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Probiotics and Placebo)
Number of subjects: 100
Study 616118527 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 2771
Study 616118527 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users (females)
Number of subjects: 2771
Study 34737837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting at Shaoshang (LU11) and Shangyang (LI1) acupuncture points, 2-3 ml volume, repeated three times (once daily)
Number of subjects: 62
Study 34737837 — intervention group
Group type: EXPERIMENTAL
Intervention: Bloodletting at Shaoshang (LU11) and Shangyang (LI1) acupuncture points
Number of subjects: 62
Study 33284838 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonemic cues intervention
Number of subjects: 40
Study 33284838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 34558993 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-resisted neck strength training (3 times weekly for 8 weeks)
Number of subjects: 28
Study 34558993 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal practice without neck-specific exercises)
Number of subjects: 28
Study 33185628 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifampridine (3,4-diaminopyridine [3,4-DAP]) at a recommended dose of 80 mg a day, divided 3 or 4 times a day.
Number of subjects: 344
Study 33185628 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifampridine (3,4-DAP) for pediatric patients.
Number of subjects: 344
Study 33185628 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifampridine (3,4-DAP)
Number of subjects: 344
Study 36011588 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi Jin Jing and resistance training (YR)
Number of subjects: 90
Study 36011588 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 90
Study 36011588 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 90
Study 35618168 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz repetitive transcranial magnetic stimulation (rTMS) over left prefrontal cortex (PFC)
Number of subjects: 40
Study 35618168 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta-burst stimulation (iTBS)
Number of subjects: 40
Study 35618168 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 40
Study 34213717 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training (PT)
Number of subjects: 169
Study 34213717 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PEP)
Number of subjects: 169
Study 32203453 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg daily (or up to 5 mg daily)
Number of subjects: 941
Study 36482613 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational music training
Number of subjects: 70
Study 33847047 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 5669
Study 33847047 — intervention group
Group type: COMPARATOR
Intervention: ramipril (ACE inhibitor)
Number of subjects: 5669
Study 32103567 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily surveys assessing PTSD symptoms
Number of subjects: 20
Study 35989622 — intervention group
Group type: EXPERIMENTAL
Intervention: Online-based health education and free access to hand cleansing and hand care products
Number of subjects: 302
Study 35989622 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 302
Study 34074291 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous periarticular injection including methylprednisolone, ropivacaine, and epinephrine at 1 day after surgery
Number of subjects: 44
Study 34074291 — intervention group
Group type: COMPARATOR
Intervention: No additional injection (control group)
Number of subjects: 44
Study 35772665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147